Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
67.42-1.10 (-1.61%)
As of 9:06 AM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close68.52
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range67.31 - 68.31
52wk Range25.29 - 68.31
1y Target EstN/A
Market Cap85.75B
P/E Ratio (ttm)20.96
Avg Vol (3m)7,511
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Forbes1 hour ago

    EpiPen Competitor Auvi-Q To Return To Market, Promising Lower Costs For Patients

    The last time Auvi-Q was sold, it didn't lower costs. Will this time be different?

  • Reuters1 hour ago

    EpiPen rival plans return to U.S. market in first-half 2017

    Privately held drugmaker Kaleo Inc announced on Wednesday plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of next year. Auvi-Q, designed to deliver the same epinephrine drug as Mylan NV's EpiPen, was recalled from the market last year amid concerns about accuracy of the dosage delivered. Mylan has come under fire from lawmakers and consumer groups for raising the list price for a pair of EpiPens to more than $600 this year from $100 in 2007 when Mylan acquired the product.

  • Bloomberg1 hour ago

    EpiPen Competitor Will Re-Launch After Being Pulled Off Market

    Mylan NV’s dominance of the U.S. allergy-shot market will be challenged next year as drugmaker Kaleo Inc. says it will resume sales of a competing product that was recalled last year.